ArticleBMC infectious diseases2026
Human parvovirus B19 seroprevalence and associated clinical and haematological findings among patients with sickle cell disease in Cameroon: a cross-sectional study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman parvovirus B19 (PVB19) is a major cause of morbidity in children with sickle cell disease (SCD), where its predilection for erythroid precursors can precipitate transient aplastic crises and life-threatening anemia. Although PVB19 is recognized as a global health concern, data on its epidemiology, clinical manifestations, and hematological consequences in African SCD populations remain limited. Recent reports suggest fluctuating PVB19 activity with periodic outbreaks, reinforcing the need for local evidence to guide diagnosis and management. This study objective is to assess the seroprevalence of human parvovirus B19 infection and explore its association with selected clinical and haematological parameters among patients with sickle cell disease.
methodsA cross-sectional study was conducted at Laquintini Hospital, Douala, from February to June 2024. A total of 120 SCD patients aged one year and above and 60 age-matched healthy controls were enrolled. Sociodemographic and clinical data were collected through questionnaires and medical records. Serum samples were analyzed for Human PVB19-specific IgM and IgG antibodies using enzyme-linked immunosorbent assay (ELISA), and hematological indices including reticulocyte counts were measured. Data were analyzed using Fisher’s exact and Mann–Whitney U tests, with univariate logistic regression to identify risk factors.
resultsThe mean age was 12.5 ± 8.0 years (range: 1–40 years) among SCD patients and 13.0 ± 7.0 years (range: 1–35 years) among controls. Parvovirus B19 IgM seroprevalence was 7.5% in SCD patients compared with 3.3% in controls, while IgG seroprevalence was 3.3% and 1.7%, respectively (IgM: p = 0.341; IgG: p = 0.666). Among SCD patients, IgM positivity was significantly associated with a higher frequency of outpatient consultations (p < 0.001), hospitalizations (p = 0.021), and vaso-occlusive crises (p = 0.035). IgM-positive patients also had significantly lower hemoglobin levels (p = 0.017) and red blood cell counts (p = 0.039). In univariate logistic regression analysis, frequent outpatient consultations (OR 27.3; 95% CI 3.68–202.3), more than three vaso-occlusive crises (OR 4.13; 95% CI 1.01–16.9), and hemoglobin levels below 7 g/dL (OR 4.93; 95% CI 1.16–21.0) were independently associated with acute PVB19 infection.
conclusionThis study provides data on the seroprevalence of human parvovirus B19 among patients with sickle cell disease in Laquintini Hospital, Douala and explores associated clinical and haematological parameters. Further large-scale longitudinal studies incorporating molecular diagnostics are warranted to better define the clinical significance of acute infection in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.